Rare predicted deleterious FEZF2 variants are associated with a neurodevelopmental phenotype
American Journal of Medical Genetics Part A · 2024-07 · 194 (7)
DOI: 10.1002/ajmg.a.63578 ↗Kurz gefasst
Fachartikel in der Zeitschrift American Journal of Medical Genetics Part A, online erschienen am 29.02.2024. Verfasst von Alison Garber und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pediatrics, Columbia University, New York, New York, USA. Hauptthemen laut MEDLINE: Intellectual Disability, Neurodevelopmental Disorders, Phenotype. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 37 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: Wellcome Trust, NICHD NIH HHS, NIA NIH HHS.
Abstract (Originalsprache)
FEZF2 encodes a transcription factor critical to neurodevelopment that regulates other neurodevelopment genes. Rare variants in FEZF2 have previously been suggested to play a role in autism, and cases of 3p14 microdeletions that include FEZF2 share a neurodevelopmental phenotype including mild dysmorphic features and intellectual disability. We identified seven heterozygous predicted deleterious variants in FEZF2 (three frameshifts, one recurrent missense in two independent cases, one nonsense, and one complete gene deletion) in unrelated individuals with neurodevelopmental disorders including developmental delay/intellectual disability, autism, and/or attention‐deficit/hyperactivity. Variants were confirmed to be de novo in five of seven cases and paternally inherited from an affected father in one. Predicted deleterious variants in FEZF2 may affect the expression of genes that are involved in fate choice pathways in developing neurons, and thus contribute to the neurodevelopmental phenotype. Future studies are needed to clarify the mechanism by which FEZF2 leads to this neurodevelopmental disorder.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pediatrics, Columbia University, New York, New York, USA.
- Department of Neurology, NYU Grossman School of Medicine, New York, New York, USA.
- GeneDx, Gaithersburg, Maryland, USA.
- Institute of Medical Genetics and Applied Genomics, University of Tübingen, Tübingen, Germany.
- Department of Pediatrics, University of North Carolina, Chapel Hill, North Carolina, USA.
- Department of Clinical and Molecular Genetics, Vall d'Hebron University Hospital, Barcelona, Spain.
ORCID-Profile: Alison Garber, Lisa S Weingarten
Förderung
- Wellcome Trust
- NICHD NIH HHS
- NIA NIH HHS
- NCATS NIH HHS
- Ministerio de Ciencia e Innovación
- NIH HHS
- National Institutes of Health
- National Center for Advancing Translational Sciences
Zitieren
APA
Garber, A., Weingarten, L. S., Abreu, N. J., Elloumi, H. Z., Haack, T., Hildebrant, C., Martínez-Gil, N., Mathews, J., Müller, A. J., Valenzuela Palafoll, I., Steigerwald, C., & Chung, W. K. (2024). Rare predicted deleterious FEZF2 variants are associated with a neurodevelopmental phenotype. American Journal of Medical Genetics Part A, 194(7). https://doi.org/10.1002/ajmg.a.63578
Vancouver
Garber A, Weingarten LS, Abreu NJ, Elloumi HZ, Haack T, Hildebrant C, et al. Rare predicted deleterious FEZF2 variants are associated with a neurodevelopmental phenotype. American Journal of Medical Genetics Part A. 2024;194(7). doi:10.1002/ajmg.a.63578
BibTeX
@article{Garber2024,
author = {Garber, Alison and Weingarten, Lisa S and Abreu, Nicolas J and Elloumi, Houda Zghal and Haack, Tobias and Hildebrant, Clara and Martínez-Gil, Núria and Mathews, Jennifer and Müller, Amelie Johanna and Valenzuela Palafoll, Irene and Steigerwald, Connolly and Chung, Wendy K},
title = {Rare predicted deleterious FEZF2 variants are associated with a neurodevelopmental phenotype},
journal = {American Journal of Medical Genetics Part A},
year = {2024},
volume = {194},
number = {7},
doi = {10.1002/ajmg.a.63578}
}
EUVIMED